EGF-Targeted Bladder Cancer Therapeutic

Back to all technologies
Download as PDF
The American Cancer Society (ACS) annually issues estimates for new cancer diagnoses and cancer deaths. For 2016, ACS estimates for bladder cancer is 76,960 new diagnoses and 16,390 deaths. Bladder cancer is the fourth and eleventh most common cancer in men and women respectively. The average age at diagnosis is 73 and 90 percent of patients are over the age 55. It is estimated that the annual national cost of bladder cancer care will reach $5.25 billion in 2020. Approximately 70 percent of newly diagnosed patients suffer disease recurrence after surgical treatment and more than 20 percent develop invasive bladder cancer. There is a need to develop efficient therapeutic strategies against this pathology.

Researchers at Purdue University have developed a therapeutic strategy using a modified bacterial toxin to target the EGF receptor and destroy bladder cancer cells. This agent proved to be superior due to its specificity and high efficacy at eliminating cancer cells, taking only minutes for treatment with enhanced safety. In animal studies, there were no toxic side effects and it was very effective against treatment-resistant tumors in dogs.

-Non-surgical treatment option
-Treatment takes minutes vs. hours
-Promising results in animal studies

Potential Applications:
-Bladder cancer treatment
May 9, 2017
Utility Patent
United States
Mar 17, 2020

Jan 17, 2020
United States

May 9, 2016
United States
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486